Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.16
-0.0510-0.82%
Volume:115.50K
Turnover:717.17K
Market Cap:423.30M
PE:-2.65
High:6.31
Open:6.18
Low:6.14
Close:6.21
Loading ...

EyePoint Pharmaceuticals Inc: $371 Mln of Cash and Investments on Dec 31, 2024, Providing Cash Runway Into 2027

THOMSON REUTERS
·
05 Mar

EyePoint Pharmaceuticals Q4 Product Sales USD 774 Thousand

THOMSON REUTERS
·
05 Mar

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire
·
05 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire
·
04 Mar

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Simply Wall St.
·
27 Feb

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

GlobeNewswire
·
26 Feb

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
25 Feb

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
17 Feb

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
17 Feb

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks
·
11 Feb

EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
06 Feb

BUZZ-EyePoint Pharma rises on eye disease drug trial data

Reuters
·
05 Feb

EyePoint Pharmaceuticals: An Undervalued Opportunity Amid Market Overreaction and Financing Concerns

TIPRANKS
·
05 Feb

EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell

MT Newswires Live
·
05 Feb

Collegium Pharmaceutical Expands Board with Nancy Lurker

TIPRANKS
·
05 Feb